Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
A Randomized, Blinded, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration in Patients With Type 1 Diabetes Mellitus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Escondido, California, United States
-
Tustin, California, United States
-
Walnut Creek, California, United States
-
-
Colorado
-
Aurora, Colorado, United States
-
-
Montana
-
Butte, Montana, United States
-
-
Texas
-
San Antonio, Texas, United States
-
-
Washington
-
Olympia, Washington, United States
-
Renton, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Give informed consent
- Aged 18 to 55 years (Part 1), Ages 18 to 65 years (Part 2)
- Stable type 1 diabetes mellitus (T1DM) for a minimum of 5 years
- Body mass index of 18-35 kg/m2
- Be C-peptide deficient (assessed by fasting concentration level)
- Normal renal function (assessed by serum creatinine)
- Be in good general health (besides T1DM)
- Have abnormal sural nerve conduction velocity observed bilaterally (Part 2 only)
Key Exclusion Criteria:
- Any significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine (except for diabetes mellitus), central nervous, or gastrointestinal condition or disease
- Unstable glucose control
- Have had a islet cell, kidney, and/or pancreas transplant
- Blood loss or blood donation within 56 days
- Drug or alcohol abuse (within 2 years) or recreational drug use (within 3 months)
- History or positive test result for Hepatitis B, C, and/or HIV
- Treatment with medication for peripheral neuropathy within 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Subcutaneous injection
|
|
Experimental: CBX129801
|
Subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the single and multiple dose pharmacokinetics of plasma CBX129801 after subcutaneous (SC) administration of CBX129801 by estimating parameters of Cmax, Tmax, Cmin, AUClast, AUCinf, Tlag, Cav, CL/F, Vz/F, and half life.
Time Frame: For duration of study / 16 months
|
Plasma CBX129801 will be used to assess the concentration versus time profiles and PK of CBX129801.
|
For duration of study / 16 months
|
|
To assess the safety and tolerability of CBX129801 when administered SC by adverse events, injection site assessments, clinical laboratory tests, vital signs, physical examinations, and electrocardiograms.
Time Frame: For duration of study / 16 months
|
For duration of study / 16 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate the technique of sensory nerve conduction velocity (SNCV) in the sural nerves in patients with type 1 diabetes mellitus.
Time Frame: Predose and 6 and 12 weeks postdose
|
Predose and 6 and 12 weeks postdose
|
|
To assess the immunogenicity of CBX129801 by occurrence of anti-CBX129801 antibody formation.
Time Frame: For duration of study / 16 months
|
For duration of study / 16 months
|
|
To evaluate the technique of motor nerve conduction velocity (MNCV) in the peroneal nerves in patients with type 1 diabetes mellitus.
Time Frame: Predose and 6 and 12 weeks postdose
|
Predose and 6 and 12 weeks postdose
|
|
To evaluate the technique of vibration perception threshold (VPT) in patients with type 1 diabetes (Part 2 only)
Time Frame: Predose and 12 weeks postdose
|
Predose and 12 weeks postdose
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CBX129801-PK-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.